News Releases

SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc . (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd

- 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be presented at ASH 2024; IND submission anticipated Q1’25 with Phase 1 initiation planned for 2025 - - Anup

SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc . (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the

- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by addressing several known causes of relapse, resulting in a potential best-in-class CAR T-cell

- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug.

Ongoing Phase 1 study informed dose selection for CARGO’s currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) 1 , in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Notable patient subset analyses show durability of

– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.

SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the

– Financing includes participation from new and existing investors –   –  Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28,

- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1